Matinas BioPharma Files 8-K: Agreements, Equity Sales, Officer Changes

TL;DR

Matinas BioPharma 8-K: Material agreements, equity sales, and exec changes filed Feb 13, 2025.

AI Summary

On February 13, 2025, Matinas BioPharma Holdings, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, unregistered sales of equity securities, and modifications to security holder rights. The report also covers the departure and election of directors and officers, changes to articles of incorporation or bylaws, and other events, alongside financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions and potential shifts in the company's structure and financial dealings, which could impact investors and stakeholders.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements, unregistered equity sales, and changes in corporate governance, suggesting potentially significant but not immediately catastrophic events.

Key Players & Entities

• Matinas BioPharma Holdings, Inc. (company) — Registrant
• February 13, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — Convertible Preferred Stock, par value $0.0001 per share (the " Preferred Stock "), in
• $1,000 — Common Stock "), with a stated value of $1,000 per share (the " Stated Value "), and w
• $1.65 million — k, for gross proceeds to the Company of $1.65 million. On the date on which the Company obtai
• $0.6393 — ed basis based on a conversion price of $0.6393 pursuant to the rules and regulations o
• $0.586 — ermined by dividing the Stated Value by $0.586 (the " Conversion Price "); provided, h
• $0.6446 — ual to 110% of the Conversion Price, or $0.6446 per share, and will expire on the five-
• $300,000 — the Offering in an amount not to exceed $300,000, with not less than $150,000 payable at
• $150,000 — to exceed $300,000, with not less than $150,000 payable at the Initial Closing. Under

Filing Documents

• form8-k.htm (8-K) — 67KB
• ex3-1.htm (EX-3.1) — 117KB
• ex4-2.htm (EX-4.2) — 135KB
• ex10-1.htm (EX-10.1) — 261KB
• ex99-1.htm (EX-99.1) — 21KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• 0001493152-25-006481.txt ( ) — 900KB
• mtnb-20250213.xsd (EX-101.SCH) — 3KB
• mtnb-20250213_lab.xml (EX-101.LAB) — 33KB
• mtnb-20250213_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: February 13, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -6-

View Full Filing

View this 8-K filing on SEC EDGAR